On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize HIV as a zoonotic infection caused by two distinct types: HIV-1, the driver of the global pandemic, and HIV-2, which is less virulent and primarily restricted to West Africa. HIV-1 is further divided into groups, with Group M (Major) responsible for over 90% of global cases and subdivided into various clades like Subtype B (common in North America) and Subtype C (dominant in Southern Africa).
- •Understand the primary mechanism of disease, which involves the depletion of through direct viral cytopathicity and chronic immune activation. This depletion leads to a predictable sequence of opportunistic infections and malignancies as the immune system fails to contain latent pathogens.
- •Identify the three clinical phases of infection: the acute phase (initial 2–4 weeks with high viremia), the chronic phase (clinical latency lasting years), and AIDS (defined by a CD4 count <200 cells/µL or the presence of an AIDS-defining illness).
- •Acknowledge the concept of the viral reservoir, which refers to anatomical compartments like the brain and lymphoid tissue where transcriptionally competent HIV genomes persist despite systemic viral suppression. This reservoir is the primary barrier to a functional cure.
- •Note the changing epidemiology where HIV is increasingly concentrated in key populations, including men who have sex with men (MSM), people who inject drugs (PWID), and migrant populations, though heterosexual transmission remains the dominant route in many high-burden regions.
Evaluation
- •Suspect (AHI) in patients presenting with a mononucleosis-like syndrome, including fever, lymphadenopathy, and a maculopapular rash, especially following high-risk exposure within the last 2–4 weeks. During this window, standard antibody tests may be negative, necessitating nucleic acid testing.
- •Order a fourth-generation HIV-1/2 antigen/antibody immunoassay as the initial screening test. This assay detects both the p24 antigen (which appears early) and HIV antibodies, significantly shortening the diagnostic window compared to older tests.
- •Confirm reactive screening results with an HIV-1/2 antibody differentiation immunoassay. If the differentiation assay is indeterminate or negative but the initial screen was positive, obtain an HIV-1 RNA nucleic acid test (NAT) to rule out acute infection.
- •Obtain a baseline CD4+ T-lymphocyte count and plasma HIV RNA (viral load) immediately upon diagnosis. The CD4 count serves as the primary marker of immunological status, while the viral load provides a baseline for monitoring treatment efficacy.
- •Perform genotypic resistance testing (GRT) before initiating ART to identify transmitted drug resistance. While ART should not be delayed for these results in a "test and treat" model, the regimen may need adjustment once results are available.
- •Screen for co-infections that complicate management, including (HBV), (HCV), and syphilis. HIV co-infection increases the odds of HBV exposure by over six-fold and significantly accelerates the progression of liver fibrosis.
- •Evaluate for latent or active (TB) using interferon-gamma release assays (IGRA) or tuberculin skin tests. In patients with advanced disease (CD4 <200 cells/µL), utilize urine TB-LAM antigen tests and Xpert Ultra to improve diagnostic yield.
- •Assess for cryptococcal antigen (CrAg) in all patients with a CD4 count <200 cells/µL. Identifying asymptomatic cryptococcemia is vital, as these patients require pre-emptive antifungal therapy to prevent lethal meningitis.
- •Calculate the nadir CD4 count, which is the lowest recorded count in the patient's history. A low nadir is a strong predictor of poor long-term immune recovery and a higher risk of non-AIDS-defining events.
- •Screen for metabolic and organ dysfunction at baseline, including a lipid panel, hemoglobin A1c, and estimated glomerular filtration rate (eGFR). Certain ART components can exacerbate renal or cardiovascular risks.
- •Identify "late presenters," defined as individuals diagnosed with a CD4 count <350 cells/µL or an AIDS-defining event. These patients require more intensive monitoring and immediate prophylaxis for opportunistic infections.
- •Rule out pregnancy in all individuals of childbearing potential, as this influences the choice of the antiretroviral backbone and requires specific counseling regarding perinatal transmission prevention.
Management
- •Implement Same-Day Initiation (SDI) of ART for all patients who are clinically stable and ready to start. Rapid initiation improves six-month retention and accelerates the time to viral suppression.
- •Administer an Integrase Strand Transfer Inhibitor (INSTI)-based regimen as the preferred first-line therapy. The standard of care is Dolutegravir (DTG) 50 mg PO once daily combined with two Nucleoside Reverse Transcriptase Inhibitors (NRTIs), typically Tenofovir and Lamivudine.
- •Utilize the fixed-dose combination of Dolutegravir 50 mg, Tenofovir Disoproxil Fumarate (TDF) 300 mg, and Lamivudine (3TC) 300 mg (TLD) as a highly effective, well-tolerated, once-daily single-tablet regimen.
- •Consider dual therapy with Dolutegravir 50 mg and Lamivudine 300 mg for treatment-naïve patients without HBV co-infection and with a baseline viral load <500,000 copies/mL to reduce long-term drug exposure.
- •Initiate primary prophylaxis for Pneumocystis jirovecii pneumonia (PCP) with Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg (one double-strength tablet) daily for all patients with a CD4 count <200 cells/µL.
- •Manage asymptomatic cryptococcal antigenemia (CrAg+) with Fluconazole 800 mg daily for 2 weeks, followed by 400 mg daily for 8 weeks. In high-risk cases, a single high-dose of liposomal amphotericin B (10 mg/kg IV) may be added to improve survival.
- •Monitor for (IRIS), a paradoxical worsening of infections after starting ART. In patients with TB, consider prophylactic Prednisone 40 mg/day for 2 weeks, then 20 mg/day for 2 weeks to reduce TB-IRIS incidence.
- •Delay ART initiation for 2–4 weeks in patients with cryptococcal meningitis and 2–8 weeks in those with tuberculous meningitis to reduce the risk of life-threatening CNS-IRIS.
- •Define viral suppression as a viral load <50 copies/mL. If the viral load remains ≥1000 copies/mL after 6 months of therapy, assess adherence and perform genotypic resistance testing to evaluate for treatment failure.
- •Switch to a second-line regimen if resistance is confirmed, typically utilizing a Protease Inhibitor (PI) like Lopinavir/Ritonavir (LPV/r) 400/100 mg twice daily or a high-barrier INSTI.
- •Transition stable, virologically suppressed patients to long-acting injectable Cabotegravir (600 mg) and Rilpivirine (900 mg) every 8 weeks if they prefer to avoid daily oral pills.
- •Prescribe Pitavastatin 4 mg daily for primary cardiovascular prevention in patients aged 40–75, even with low traditional risk scores, as HIV-related inflammation significantly increases atherosclerotic risk.
- •Avoid monotherapy or dual therapy (outside of specific approved combinations like DTG/3TC), as these strategies rapidly lead to the development of multi-drug resistance.
- •Refer patients for specialized care if they are "immunological non-responders" (INR)—those who maintain viral suppression but fail to increase their CD4 count above 500 cells/µL after 2 years of ART.
- •Monitor renal function and bone mineral density in patients on TDF-based regimens. If eGFR drops or bone loss is significant, consider switching to Tenofovir Alafenamide (TAF) or a tenofovir-sparing regimen.
Board Review — High Yield
- •U=U — Undetectable equals Untransmittable; viral load <200 copies/mL prevents sexual transmission.
- •4th Gen Assay — Detects p24 antigen and antibodies; reduces the window period to ~14-20 days.
- •PCP Prophylaxis — Start TMP-SMX when CD4 <200 cells/µL; stop when CD4 >200 for >3 months on ART.
- •IRIS — Paradoxical clinical worsening after ART initiation due to immune recovery; common with TB and Cryptococcus.
- •Dolutegravir — Preferred INSTI due to high genetic barrier to resistance and once-daily dosing.
- •START Trial — Proved that immediate ART initiation at any CD4 count reduces morbidity and mortality.
- •Elite Controllers — Rare individuals who maintain undetectable viral loads without ART; still require monitoring.
- •Mpox — Severity is CD4-dependent; patients with CD4 <200 are at high risk for necrotizing, fatal disease.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification of HIV
- ▸HIV-1 Group M is the primary driver of the global pandemic and is subdivided into subtypes A-L and various Circulating Recombinant Forms (CRFs) [1, 12].
- ▸Late diagnosis is defined by a CD4 count **<350 cells/µL**, while very late diagnosis is defined by a CD4 count **<200 cells/µL** [13, 15].
- ▸HIV-1 and HIV-2 originated from independent zoonotic transmissions of SIV from African primates to humans in the early 20th century [3].
Human Immunodeficiency Virus (HIV) is a that serves as the primary causative agent of Acquired Immune Deficiency Syndrome (AIDS) [1]D. It is characterized by a chronic, progressive infection that targets and depletes , leading to profound immunosuppression and susceptibility to opportunistic infections and malignancies [4]D[5]C. HIV is categorized into two distinct types, HIV-1 and HIV-2, both of which originated from multiple independent zoonotic transmissions of simian immunodeficiency viruses (SIVs) infecting African great apes in the early 20th century [3]D. HIV-1, specifically the Group M lineage, is the principal strain responsible for the global pandemic [1]D[3]D.
Synonyms and Nomenclature
Also Called: HIV, Human Immunodeficiency Virus, AIDS virus (historical), Lymphadenopathy-associated virus (LAV, historical), Human T-lymphotropic virus type III (HTLV-III, historical).
Related Terms:
- HIV-1: The most common and pathogenic type of HIV [3]D.
- HIV-2: A less virulent type primarily restricted to West Africa [3]D.
- SIV (Simian Immunodeficiency Virus): The ancestral virus from which HIV emerged via cross-species transmission [1]D.
Definitions of Clinical Phases and Stages
The progression of HIV infection is defined by specific temporal and immunological milestones. Understanding these terms is critical for clinical staging and determining the urgency of (ART).
- Acute Infection (Prodromal Phase): The initial period (typically 2–4 weeks) following viral entry, characterized by high-level viremia and rapid dissemination to lymphoid tissues [13]D. Patients may experience a mononucleosis-like syndrome during this phase.
- Chronic Phase (Clinical Latency): A period of long-term viral persistence where the virus continues to replicate at lower levels [1]D[4]D. In the absence of treatment, this phase can last several years, during which intrahost viral evolution occurs [5]C.
- Nadir: The lowest recorded CD4+ T-cell count in a patient's clinical history [13]D. A low nadir is often a marker of significant prior immune damage and may predict poorer long-term recovery.
- Plateau (Set Point): The stable level of plasma HIV RNA reached after the initial acute infection phase, which reflects the balance between viral replication and the host immune response.
- Late Diagnosis (Late Presenter): A clinical definition for individuals diagnosed with HIV when their immune system is already significantly compromised. The consensus threshold for a late diagnosis is a CD4 count <350 cells/µL or the presence of an AIDS-defining event at the time of diagnosis [13]D[15]D.
- Very Late Diagnosis: Defined as a CD4 count <200 cells/µL at the time of initial diagnosis [15]D.
- Viral Reservoir: Anatomical compartments (e.g., the brain, lymphoid tissue) where transcriptionally competent HIV genomes persist despite systemic viral suppression with ART [7]D.
Classification of HIV-1 Groups and Subtypes
HIV-1 is characterized by extreme genetic diversity resulting from high mutation rates and frequent recombination [4]D[16]D. It is classified into four distinct groups (M, N, O, and P), representing four separate zoonotic spillover events [1]D[3]D.
Group M (Major)
Group M is responsible for over 90% of global infections [1]D. It is further subdivided into several phylogenetically distinct clades or subtypes (A, B, C, D, F, G, H, J, K, and L) [12]D[16]D.
- Subtype B: Predominant in North America, Western Europe, and Australia [10]D[15]D.
- Subtype C: The most prevalent subtype globally, dominant in Southern Africa and India [12]D[16]D.
- Subtype A (including A6): Common in Eastern Europe and Central Asia [14]D[19]D.
- Subtype F1: Historically significant in Romania and parts of South America [15]D[17]D.
Recombinant Forms
When an individual is co-infected with two different subtypes, the virus can undergo recombination, leading to new genetic variants [17]D.
- Circulating Recombinant Forms (CRFs): Recombinant lineages that have established stable transmission in a population (e.g., CRF01_AE, CRF02_AG) [10]D[11]D.
- Unique Recombinant Forms (URFs): Recombinant viruses identified in single individuals that have not yet established widespread transmission [17]D.
Molecular and Transmission Clusters
Modern classification increasingly relies on to identify transmission clusters, which are groups of infections linked by high genetic similarity (often a genetic distance threshold of ≤0.005 or 0.9% depending on the region) [8]D[20]D. These clusters help public health officials track outbreaks in specific populations, such as migrant groups, men who have sex with men (MSM), or healthcare settings like dialysis units [8]D[9]D[11]D.
| Group | Designation | Prevalence/Distribution | Key Features |
|---|---|---|---|
| M | Major | >90% of global cases | Contains subtypes A-L and CRFs; contains the ASP ORF [1]D[12]D |
| O | Outlier | Restricted to West/Central Africa | Highly divergent from Group M [3]D |
| N | Non-M, Non-O | Extremely rare (Cameroon) | Result of SIVcpz transmission [3]D |
| P | Pending | Extremely rare (Cameroon) | Closely related to SIVgor (gorillas) [3]D |
| Category | CD4 Threshold | Clinical Implication |
|---|---|---|
| Acute Infection | Variable (often high) | High transmissibility; high viral load [13]D |
| Late Presenter | <350 cells/µL | Increased risk of morbidity and mortality [13]D[15]D |
| Very Late Presenter | <200 cells/µL | High risk for immediate opportunistic infections [15]D |
| Advanced HIV Disease | <200 cells/µL | Requires screening for cryptococcus and TB [15]D |
Epidemiology and Risk Factors
- ▸HIV prevalence varies significantly by region, with adult prevalence in Sierra Leone at **1.6-1.7%** and a high burden of **17 new cases/day** in Guinea [43, 48].
- ▸Key populations, including MSM, FSW, and migrants, remain the primary drivers of transmission clusters and require targeted AHI screening [8, 33, 37].
- ▸Comorbidities like hypertension (22% prevalence) and depression significantly impact the long-term management of PLHIV [21, 22].
The global of (HIV) has transitioned from an acute epidemic to a manageable chronic disease model due to the widespread implementation of (ART) [45]D[47]D. However, significant regional disparities persist, particularly in sub-Saharan Africa and Southeast Asia, where transmission dynamics are influenced by a complex interplay of biological, behavioral, and structural factors [43]D[48]D.
Global and Regional Prevalence
In sub-Saharan Africa, the burden remains disproportionately high. In Sierra Leone, the adult HIV prevalence is estimated at 1.6% to 1.7%, representing approximately 82,000 people living with HIV (PLHIV) [43]D. In Guinea, the epidemic results in approximately 17 new infections and 10 deaths daily [48]D. Conversely, in high-income settings like the United States, the stability of the epidemic relies heavily on public health infrastructure; simulation models suggest that the cessation of support services (e.g., Ryan White program) could result in 69,695 additional infections over five years, a 68% increase (95% CrI: 18%–118%) [39]D.
Transmission Dynamics and Key Populations
HIV transmission is concentrated within specific key populations, though the primary drivers vary by geography.
- Men who Have Sex with Men (MSM): In Indonesia, MSM represent a critical key population with an escalated epidemic. Identifying (AHI) in this group is vital, as the early phase carries the highest transmission risk [37]D.
- Female Sex Workers (FSW): Inconsistent condom use remains the most proximal behavioral risk factor for FSWs in Africa [33].
- Migrant Populations: In Hangzhou, China, permanent migrant populations (PMP) are characterized by younger age and predominantly homosexual transmission, forming large molecular transmission clusters with non-migrant populations [8]D.
- Adolescent Girls and Young Women (AGYW): While HIV incidence among AGYW in eastern and southern Africa has declined substantially, mathematical modeling indicates this is due to a combination of biomedical prevention and behavioral changes [46]D.
Risk Factors for Acquisition and Progression
Risk factors for HIV acquisition include biological vulnerabilities and behavioral patterns. Notably, concerns regarding adenovirus type 5 (Ad5) vector-based vaccines increasing HIV susceptibility have been refuted; a Phase 3 trial of 44,247 participants demonstrated that Ad5-nCoV vaccination does not increase the likelihood of HIV infection [25].
Progression and clinical outcomes are heavily influenced by comorbidities. In Ethiopia, the pooled prevalence of among PLHIV is 22% (95% CI: 17.0–28.0), driven by physical inactivity and alcohol consumption [21]. Furthermore, underweight status (BMI <5th percentile) at ART initiation is a significant predictor of detectable viral load (≥1,000 copies/mL) in adolescents [32].
Temporal Trends and Co-infections
There is a re-emergence of sexually transmitted infections (STIs) among PLHIV. In Korea and Japan, the incidence of syphilis has shown a significant upward trend among working-age populations and PLHIV [30][38]D. Co-infection with other viruses also complicates the epidemiological landscape; for instance, HIV co-infection increases the odds of Hepatitis B exposure by 6.23 times [26]. In the Peruvian Amazon, co-infection with HTLV-1/2 is prevalent and may influence clinical progression [44]D.
Protocol: Risk Stratification for Acute HIV Infection (AHI)
Clinicians should utilize risk-stratified testing to identify AHI during the window period when antibody tests may be negative [37]D.
- Step 1: Clinical Screening: Evaluate for symptoms of acute viral syndrome (fever, lymphadenopathy, rash).
- Step 2: Behavioral Assessment: Identify high-risk exposures within the last 2–4 weeks (e.g., condomless anal intercourse, shared injection equipment).
- Step 3: Risk Scoring: Apply validated tools, such as the four-item risk score (e.g., age, specific sexual behaviors), to determine the need for HIV-PCR testing [37]D.
- Step 4: Diagnostic Testing: If antibody-negative but high-risk, perform nucleic acid amplification testing (NAAT) to detect viral RNA [37]D.
| Factor | Association (OR/RR) | Evidence Level |
|---|---|---|
| Physical Inactivity (Hypertension in HIV) | AOR 2.73 (95% CI: 2.05-3.41) | 2a [21] |
| HIV Co-infection (HBV Exposure) | aOR 6.23 (p=0.009) | 2b [26] |
| Underweight (Detectable Viral Load) | Significant Association | 2b [32] |
| Substance Abuse (Suicide Risk) | 3x higher than general population | 2b [31] |
| Advanced HIV (COVID-19 Mortality) | Increased Risk (CD4 <200) | 2b [34] |
| Ad5-nCoV Vaccine (HIV Acquisition) | No increased risk | 1b [25] |
Management of HIV Infection
- ▸Same-day ART initiation (SDI) is the standard of care to maximize retention and viral suppression.
- ▸Dolutegravir-based regimens are preferred for first-line therapy due to high efficacy and a high genetic barrier to resistance, despite associations with weight gain.
- ▸Viral suppression thresholds are tiered: <50 copies/mL (optimal/untransmittable), <200 copies/mL (clinically suppressed), and <1000 copies/mL (controlled).
The of HIV has transitioned from treating an acute, terminal illness to the long-term coordination of a chronic condition [71]D. Modern antiretroviral therapy (ART) aims to achieve rapid and sustained viral suppression, which facilitates immune reconstitution, prevents onward transmission, and reduces HIV-associated morbidity and mortality [55][70]D. Effective management requires a multidisciplinary approach addressing pharmacological, psychological, and nutritional factors [50][64]D.
Step 1: Initial Assessment and Severity Classification
Upon diagnosis, clinicians must immediately assess the patient's clinical and immunological status to guide treatment urgency.
- Baseline Evaluation: Obtain a CD4+ T-lymphocyte count and plasma HIV RNA (viral load). A CD4 count <200 cells/mm³ indicates severe immunosuppression and a high risk for opportunistic infections [58].
- Severity Classification: Patients are classified as having mild, moderate, or severe disease based on CD4 thresholds and clinical symptoms. Severe immunosuppression (CD4 <200 cells/mm³) requires immediate ART initiation and potential prophylaxis for opportunistic infections [58].
- Disposition: Most patients can be managed in the outpatient setting. However, those with acute opportunistic infections or severe wasting (BMI <18.5 kg/m²) may require hospitalization for stabilization [32][45]D.
Step 2: Rapid Initiation of Antiretroviral Therapy (ART)
Global guidelines now emphasize the "test and treat" strategy, specifically Same-Day Initiation (SDI) of ART [53].
- Protocol: Administer the first dose of ART on the day of diagnosis if the patient is clinically stable and ready to start [53]. Implementation of the ART Same-Day Counseling and Initiation (ASCI) protocol has been shown to improve six-month retention and viral suppression rates (Level 1b) [53].
- Drug of Choice: Integrase Strand Transfer Inhibitor (INSTI)-based regimens, specifically Dolutegravir (DTG) 50 mg PO once daily, are the preferred first-line agents [51][59].
- Rationale: DTG is preferred over Efavirenz (EFV) due to its superior genetic barrier to resistance and better tolerability [60]. In a target trial emulation, DTG-based regimens achieved high rates of suppression, though they were associated with a mean weight increase of 2.9 kg more than EFV-based regimens over 12 months [51].
Step 3: Selection of Maintenance Regimens
Standard ART consists of a three-drug regimen, typically comprising two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and a third agent from a different class [52][57].
- First-line Regimen: Dolutegravir 50 mg + Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg (or Emtricitabine) [59][60].
- Alternative Regimen: For patients unable to tolerate INSTIs, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) like Efavirenz 600 mg PO daily or Nevirapine 200 mg PO daily (after a 14-day lead-in) may be used [54][57]. However, NNRTIs have a lower genetic barrier to resistance [23].
- Long-Acting Options: For patients with demonstrated viral suppression, long-acting injectable Cabotegravir (CAB) 600 mg and Rilpivirine (RPV) 900 mg administered intramuscularly every 8 weeks offers a convenient alternative that may improve adherence [65]D.
Step 4: Monitoring and Titration
Monitoring focuses on virologic success and the recovery of the immune system.
- Viral Load Monitoring: Measure viral load at 3 months and 6 months after initiation, then every 6–12 months [70]D.
- Target: Viral suppression is ideally defined as <50 copies/mL (untransmittable), though <200 copies/mL is considered clinically suppressed [70]D.
- Immunological Recovery: CD4 counts should be monitored every 3–6 months. The goal is a CD4 count ≥500 cells/mm³ [58]. Factors such as older age at initiation and lower baseline CD4 counts are associated with a higher risk of being an "immunological non-responder" (INR), where viral load is suppressed but CD4 recovery is inadequate [56][62]D.
- Metabolic and Organ Monitoring: Monitor BMI, blood pressure, and renal function. Switching from EFV to DTG has been associated with significant increases in weight and BMI, but improvements in lipid profiles (decreased LDL and triglycerides) [60].
Step 5: Management of Treatment Failure and Resistance
Treatment failure is defined as a persistent viral load ≥1000 copies/mL after at least 6 months of ART [32][36]D.
- Assess Adherence: Evaluate for barriers such as depression (HSCL-25 score >1.75) or medication burden in older adults with polypharmacy [64]D[68]D.
- Genotypic Resistance Testing (GRT): If failure is confirmed, perform GRT to identify mutations. In some regions, up to 60.6% of patients with viraemia harbor at least one drug-resistance mutation [23]. Resistance to NRTIs (41.2%) and NNRTIs (38.6%) is common [23].
- Switch to Second-line: Transition to a regimen containing a Protease Inhibitor (PI) or a high-barrier INSTI. Common second-line options include Lopinavir/Ritonavir (LPV/r) 400/100 mg twice daily or Atazanavir/Ritonavir (ATV/r) 300/100 mg once daily [55][57].
What NOT to Do
- Do NOT delay ART initiation while waiting for baseline laboratory results unless there is a clinical suspicion of cryptococcal meningitis or TB meningitis, where immediate ART may increase the risk of Immune Reconstitution Inflammatory Syndrome (IRIS) [53].
- Do NOT use monotherapy or dual therapy for initial treatment (except in specific clinical trials), as this rapidly leads to the development of drug resistance [52].
- Do NOT ignore mental health comorbidities. Depressive symptoms are associated with a significantly increased risk of all-cause mortality and treatment interruption [64]D. Integrated music and counseling programs have been shown to improve self-esteem and ART adherence in young adults [50].
| Drug | Class | Standard Dose | Key Adverse Effects | Evidence Level |
|---|---|---|---|---|
| Dolutegravir (DTG) | INSTI | 50 mg PO daily | Weight gain, insomnia, hyperglycemia | 1b [51][60] |
| Efavirenz (EFV) | NNRTI | 600 mg PO daily | Neuropsychiatric symptoms, dyslipidemia | 1b [51][54] |
| Nevirapine (NVP) | NNRTI | 200 mg PO daily | Hepatotoxicity, severe rash (SJS/TEN) | 1b [54] |
| Tenofovir (TDF) | NRTI | 300 mg PO daily | Renal impairment, bone mineral density loss | 2b [58] |
| Lopinavir/r (LPV/r) | PI | 400/100 mg BID | Diarrhea, dyslipidemia, GI distress | 2b [55] |
| Cabotegravir (LA) | INSTI | 600 mg IM q8w | Injection site reactions | 5 [65]D |
Supportive Care and Complication Management
- ▸Late presentation (CD4 < 350 cells/μL) occurs in 50% of cases and necessitates immediate OI screening and prophylaxis.
- ▸Same-day ART is non-inferior to deferred ART in patients with TB symptoms and should be prioritized to ensure viral suppression.
- ▸IRIS affects up to 25% of patients; TB-IRIS risk can be mitigated with prophylactic prednisone in high-risk individuals.
Supportive care in HIV focuses on the prevention of opportunistic infections (OIs), the mitigation of the (IRIS), and the management of chronic co-morbidities. Approximately 50% of new HIV diagnoses globally are classified as late presentations, defined by a CD4+ count below 350 cells/μL or the presence of an AIDS-defining condition [80]D. These patients require aggressive supportive protocols to reduce the high risk of morbidity and mortality associated with advanced immunosuppression [80]D[84]D.
Step 1: Prophylaxis and Screening for Opportunistic Infections
Initial management must prioritize the prevention of OIs based on CD4+ thresholds.
- Pneumocystis jirovecii pneumonia (PCP): Administer Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg (one double-strength tablet) daily for all patients with CD4+ counts < 200 cells/μL [73]. TMP-SMX remains the gold standard for both primary and secondary prophylaxis due to its superior efficacy compared to dapsone-based regimens, aerosolized pentamidine, or atovaquone [73].
- Cryptococcal Disease: Screen all patients with CD4+ < 200 cells/μL for cryptococcal antigen (CrAg). For asymptomatic CrAg-positive patients with low titers, the addition of a single high-dose of liposomal amphotericin B (10 mg/kg IV) to standard fluconazole pre-emptive therapy has been shown to improve meningitis-free survival [75].
- Tuberculosis (TB): TB is the leading cause of hospitalization and death in people living with HIV (PWH) [84]D. Screening should involve Xpert Ultra and urine TB-LAM antigen tests, which are associated with improved survival in advanced disease [84]D.
Step 2: Strategic ART Initiation
The timing of antiretroviral therapy (ART) initiation is critical, particularly in the context of co-infections.
- TB-Symptomatic Patients: In outpatients with at least one TB symptom, same-day ART initiation is non-inferior to deferring ART until TB diagnostic results are available regarding 6-month viral suppression [74]. This approach simplifies the care cascade and reduces the risk of loss to follow-up [74].
- CNS Infections: Caution is required in central nervous system (CNS) infections like or cryptococcal meningitis, where immediate ART can trigger life-threatening IRIS [86]D[88]D.
Step 3: Management of Immune Reconstitution Inflammatory Syndrome (IRIS)
IRIS occurs in 10%–25% of patients initiating ART, manifesting as a paradoxical worsening of a known infection or the unmasking of a subclinical one [87]D.
- Risk Assessment: Identify high-risk patients (pre-ART CD4+ < 100 cells/μL, high viral load, or specific HLA alleles such as DRB1*01:02) [78].
- Prophylaxis: In patients with TB starting ART, prophylactic prednisone (40 mg/day for 2 weeks, then 20 mg/day for 2 weeks) can reduce the incidence of TB-IRIS [78].
- Treatment: Most IRIS cases are managed with continued ART and anti-inflammatory therapy. For severe neurological IRIS, such as cortical encephalitis following cryptococcal meningitis, prolonged or recurrent steroid courses may be necessary [92]C.
- Special Considerations: PJP-IRIS is rare (2.7%–4% of IRIS cases) but requires careful differentiation from treatment failure [83]D. Immune recovery uveitis (IRU) can cause vision loss in patients with prior CMV retinitis and may require intravitreal steroids [89]D.
Step 4: Management of Mycobacterial and Rheumatic Complications
Advanced HIV often involves complex mycobacterial infections beyond M. tuberculosis, including Mycobacterium avium complex (MAC).
- MAC Treatment: Standard therapy includes Azithromycin 500–600 mg daily, Ethambutol 15 mg/kg daily, and Rifabutin 300 mg daily [91]C. MAC can present as spindle cell pseudotumors in the spinal cord or intracranial ring-enhancing lesions, often requiring multidisciplinary management [90]C[91]C.
- Rheumatic Manifestations: PWH frequently experience arthralgia, , and inflammatory myopathies [81]D. These are often linked to immune dysregulation rather than HLA-B27 and may occur at any stage of infection [81]D.
- Adjunctive Therapy: Emerging evidence suggests that Glutathione (GSH) may enhance antibiotic efficacy and reduce inflammation in HIV-TB co-infections of the CNS by mitigating oxidative stress and immune dysfunction [76].
Step 5: Monitoring and Treatment Failure
Failure to improve despite appropriate therapy should trigger an evaluation for drug resistance, drug-drug interactions (especially with rifampin), or paradoxical IRIS [82]D[86]D. In cases of suspected cryptococcal relapse versus IRIS, cerebrospinal fluid (CSF) culture is essential, though CD4+ counts and CSF white cell counts are often unreliable for differentiation [88]D.
| Condition | Drug | Dose/Route | Duration | Evidence Level |
|---|---|---|---|---|
| PCP Prophylaxis | TMP-SMX | 160/800 mg PO daily | Until CD4 > 200 for 3 months | 1a [73] |
| Cryptococcal (Asymptomatic) | Liposomal Amphotericin B | 10 mg/kg IV (single dose) | Combined with Fluconazole | 1b [75] |
| TB-IRIS Prophylaxis | Prednisone | 40 mg PO daily (2 wks), then 20 mg (2 wks) | 4 weeks total | 1b [78] |
| MAC Infection | Azithromycin + Ethambutol + Rifabutin | 500mg + 15mg/kg + 300mg PO daily | Minimum 12 months | 4 [91]C |
| Drug-Susceptible TB | HRZE Regimen | Standard WHO weight-based dosing | 6 months | 5 [79]D |
Prognosis and Long-term Outcomes
- ▸Mpox severity in PLWH is highly CD4-dependent, with significant mortality risk when CD4 counts are below 200 cells/μL.
- ▸Approximately 15–30% of patients remain immunological non-responders despite viral suppression, increasing their risk for non-AIDS comorbidities.
- ▸Long-term survival is now comparable to the general population for those who initiate ART early and maintain a high CD4/CD8 ratio.
The prognosis for people living with HIV (PLWH) has been radically transformed by the advent of potent antiretroviral therapy (ART). In the modern era, HIV is managed as a chronic manageable condition rather than a terminal illness. However, long-term outcomes are heavily influenced by the timing of ART initiation, baseline immune status, and the presence of non-communicable comorbidities [27][56]. While many patients achieve near-normal life expectancy, a subset remains at risk for immunological non-response, metabolic dysfunction, and specific malignancies [56][106][108].
Survival and Mortality Predictors
Survival rates among PLWH have improved significantly under 'test and treat' strategies, yet preventable mortality persists, particularly in resource-limited settings [27]. A retrospective cohort study in Ethiopia (2016–2023) demonstrated that while ART coverage is near-universal, mortality remains higher in patients with advanced WHO clinical stages (III or IV) and those with low baseline CD4 counts [27].
Key predictors of mortality include:
- Baseline CD4 count < 200 cells/μL: Significantly increases the risk of opportunistic infections and early death [27][110]C.
- Co-infections: Active tuberculosis (TB), particularly rifampicin-resistant TB (RR-TB), remains a major driver of poor outcomes, although treatment success for RR-TB can reach high levels with modern regimens [105].
- Malignancy: Aggressive cancers like (DLBCL) carry a high mortality risk; in some cohorts, the 5-year survival rate for DLBCL in PLWH remains a challenge due to late diagnosis and treatment complexities [108].
Immune Reconstitution Patterns
Successful ART is defined by sustained virological suppression (HIV-1 RNA < 50 copies/mL), which typically leads to CD4 T-cell recovery [94][98]. However, approximately 15–30% of patients are classified as "immunological non-responders" (INR), failing to achieve a CD4 count > 500 cells/μL despite years of viral suppression [56].
Long-term immune recovery follows a specific trajectory: CD4 counts often rise rapidly in the first 12–24 months, followed by a slower plateau phase [56]. Factors associated with poor immune reconstitution include older age at ART initiation, lower baseline CD4/CD8 ratios, and persistent systemic inflammation [56]. A low CD4/CD8 ratio is a marker of residual immune dysregulation and is associated with an increased risk of non-AIDS-defining events [56]. In rare cases, rapid immune recovery can trigger Immune Reconstitution Inflammatory Syndrome (IRIS), such as cortical encephalitis following cryptococcal meningitis, which may require individualized immunotherapy [92]C.
Long-term Metabolic and Organ Sequelae
As PLWH age, the focus of care shifts to managing chronic comorbidities. Chronic inflammation and ART-related toxicities contribute to several long-term issues:
- Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): This has emerged as a significant comorbidity. Prognostic markers such as the lymphocyte-to-high-density lipoprotein cholesterol ratio (LHR) and the aggregate index of systemic inflammation (AISI) are used to predict MAFLD risk [106].
- Cardiovascular and Metabolic Events: PLWH, especially those with HCV co-infection, face increased risks of diabetes and hyperlipidemia even after HCV clearance [107].
- Renal Disease: HIV-associated glomerular disease can lead to nephrotic-range proteinuria. While calcineurin inhibitors like tacrolimus (titrated to clinical response) can induce remission, long-term use may increase the risk of late-onset [112]C.
- Bone Health: Long-term use of certain ART components (e.g., TDF) is linked to bone mineral density (BMD) loss. Transitioning to short-cycle regimens (e.g., 3-day-per-week efavirenz/emtricitabine/tenofovir) has been studied to reduce long-term toxicities while maintaining suppression [97].
Prognosis in Specific Populations
Pregnancy and Perinatal Outcomes
WLHIV face higher risks of pregnancy complications and adverse perinatal outcomes compared to HIV-negative women [103]. These risks include preterm birth and low birth weight, which were further exacerbated by healthcare disruptions during the pandemic [103]. Additionally, WLHIV undergoing excisional treatment for high-grade cervical intraepithelial neoplasia (CIN) require close monitoring, as the risk window for persistent HPV infection is extended due to increased life expectancy [101][104].
[[Mpox]] Co-infection
Mpox severity is strictly CD4-dependent. Patients with CD4 counts < 200 cells/μL are at high risk for severe, necrotic, and potentially fatal mpox [93][110]C. In contrast, PWH with well-controlled HIV (CD4 > 500 cells/μL) generally experience clinical outcomes similar to HIV-negative individuals [93].
Virologic Failure and Recurrence Risk
While modern single-tablet regimens (STRs) like bictegravir/lenacapavir or doravirine/islatravir show high efficacy, virologic failure can still occur [94][98][99]. Failure is often linked to adherence challenges, but may also arise from specific mutations. For instance, the Y181C mutation has been associated with failure in patients on long-acting injectable cabotegravir/rilpivirine, particularly in the context of intensive intravenous drug use (chemsex) [113]C. Differentiated Service Delivery (DSD) models have proven effective in maintaining high rates of viral suppression and retention in care for stable patients [100].
Protocol for Long-term Comorbidity Surveillance
Step 1 → Baseline Assessment: Establish baseline CD4/CD8 ratio, metabolic profile (lipids, A1c), and renal function (eGFR, proteinuria) [56][106][112]C. Step 2 → Routine Monitoring: Conduct HIV-1 RNA and CD4 testing every 6 months for stable patients. Perform annual screening for MAFLD using inflammatory metabolic parameters [56][97][106]. Step 3 → Malignancy Screening: Implement regular for WLHIV and maintain high clinical suspicion for EBV-associated tumors or Kaposi Sarcoma in patients with history of low CD4 counts [101][102][111]C. Step 4 → Lifestyle Modification: Integrate tobacco cessation interventions, as PLWH have significantly higher smoking rates, which compounds cardiovascular and mortality risks [96].
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Baseline CD4 Count | > 500 cells/μL | < 200 cells/μL [27][93] |
| Viral Load | Undetectable (< 50 copies/mL) | Persistent viremia or blips [94][113]C |
| CD4/CD8 Ratio | Normalizing (> 0.4–0.5) | Persistently low (< 0.3) [56] |
| WHO Stage | Stage I or II | Stage III or IV [27] |
| Co-infections | None or successfully treated | Active RR-TB, HHV-8, or HCV [105][102][107] |
| Adherence | High (STR or DSD models) | Poor (Complex regimens, IV chemsex) [94][100][113]C |
Landmark Trials and Key Evidence
- ▸The START trial established that immediate ART initiation at CD4+ counts >500 cells/mm³ improves clinical outcomes and is superior to deferred treatment.
- ▸The ECHO trial demonstrated no significant difference in HIV acquisition risk between DMPA-IM, Cu-IUD, and LNG implants, though mucosal target cell frequencies may vary.
- ▸Statin therapy (pitavastatin 4 mg daily) is being utilized to address the heightened cardiovascular and inflammatory risks in the aging HIV population.
The of HIV has been fundamentally reshaped by large-scale randomized controlled trials (RCTs) that shifted the paradigm from "watchful waiting" to immediate therapeutic intervention. These trials provide the evidence base for current global guidelines regarding the timing of antiretroviral therapy (ART) initiation, the safety of hormonal contraception in high-prevalence areas, and the management of non-communicable comorbidities in aging populations living with HIV.
The START Trial: Redefining ART Initiation
The Strategic Timing of Antiretroviral Treatment (START) trial is the definitive evidence for immediate ART initiation regardless of CD4+ count. Prior to START, clinicians often deferred ART until CD4+ counts dropped below 350 or 500 cells/mm³ to avoid long-term toxicity. START randomized 4,684 ART-naïve adults with CD4+ counts >500 cells/mm³ to either immediate ART or deferred ART (until CD4+ fell below 350) [116].
Key findings from the START trial and its sub-studies include:
- Clinical Benefit in Low Viremia: Even participants with low pretreatment viremia (<3000 copies/mL) derived benefit from immediate ART, showing improved clinical outcomes and CD4+ recovery [125].
- Kidney Health: While immediate ART was associated with a small but statistically significant decline in estimated glomerular filtration rate (eGFR) over a median of 2.1 years compared to deferred therapy, the long-term renal benefits of viral suppression generally outweigh the risks of ART-related nephrotoxicity [116].
- and Inflammation: Baseline levels of inflammatory biomarkers, specifically interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP), were found to be associated with prevalent and incident hypertension in this cohort, suggesting that HIV-related inflammation contributes to cardiovascular risk even at high CD4+ counts [124].
- CD4+ Recovery Challenges: Despite starting ART at high CD4+ levels, 39.7% of participants experienced "low CD4 recovery" (an increase of <50 cells/mm³ after 8 months). Risk factors for poor recovery included male sex and lower baseline CD4+ counts [128].
- Genetic Influence: Genome-wide screens within the START cohort identified significant associations between single-nucleotide polymorphisms (SNPs) in the MHC class I region and viral load set points, highlighting the role of host genetics in viral replication [127].
The ECHO Trial: Contraception and HIV Acquisition
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial addressed a long-standing concern regarding whether injectable progestins increased HIV susceptibility. This open-label RCT randomized 7,829 women to intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (Cu-IUD), or a levonorgestrel (LNG) implant [121].
The trial found no substantial difference in HIV acquisition risk between the three methods [117]. However, sub-studies revealed complex biological interactions:
- Mucosal Changes: Initiation of DMPA-IM was found to increase the frequency of Th17-like HIV target cells in the genital tract, which are preferential targets for infection [119].
- Cytokine Profiles: While the trial showed clinical equivalence, certain cervicovaginal cytokines were altered following contraceptive initiation, though these did not translate to a higher rate of seroconversion in the primary analysis [120].
- PrEP Integration: During the final year of the ECHO trial, oral pre-exposure prophylaxis (PrEP) was integrated into the standard of care. This integration was feasible and essential, as many women remained at high risk despite using effective contraception [122][123]. Objective markers (plasma tenofovir) confirmed that while uptake was high, consistent adherence remained a challenge for some participants [118].
REPRIEVE: Cardiovascular and Non-CVD Prevention
As the HIV population ages, managing non-AIDS-defining events has become a priority. The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) evaluated the use of pitavastatin 4 mg daily in a global cohort. While primarily a cardiovascular trial, secondary analyses assessed its impact on major non-cardiovascular disease (non-CVD) events, including AIDS-defining events and non-AIDS-defining cancers [115]. The trial underscores the pleiotropic effects of in reducing the chronic inflammatory state associated with HIV [115].
Behavioral Interventions: The PARTNER Study
Beyond pharmacotherapy, behavioral evidence is critical for high-risk groups. The PARTNER study evaluated a 4-session adapted motivational interviewing intervention for sexual minority men aged 18-35. The intervention successfully reduced cannabis and illicit drug use while increasing PrEP uptake and reducing condomless anal sex with casual partners [114]. This highlights the necessity of combining biomedical prevention (PrEP) with structured behavioral support to mitigate HIV transmission risk [114].
| Trial | Year | N | Intervention | Key Finding |
|---|---|---|---|---|
| START [116] | 2015 | 4,684 | Immediate vs. Deferred ART | Immediate ART reduces serious AIDS and non-AIDS events by 57%. |
| ECHO [117] | 2019 | 7,829 | DMPA-IM vs. Cu-IUD vs. LNG Implant | No significant difference in HIV acquisition risk between contraceptive methods. |
| REPRIEVE [115] | 2023 | 7,769 | Pitavastatin 4 mg daily vs. Placebo | Statins reduce major adverse cardiovascular events and impact non-CVD outcomes. |
| PARTNER (MI) [114] | 2024 | 196 | Adapted Motivational Interviewing | Reduced substance use and increased PrEP uptake in sexual minority men. |
Prevention and Screening
- ▸PEP must be initiated within 72 hours of exposure and continued for 28 days to be effective.
- ▸Long-acting injectable PrEP, such as 6-monthly Lenacapavir, offers a solution to daily adherence challenges but requires careful management of the 2-8 week 'bridge period'.
- ▸Integrated screening for HIV and bacterial STIs is mandatory for high-risk populations, as co-infections significantly increase transmission risk.
Prevention of HIV infection has evolved from a reliance on behavioral modification to a comprehensive biomedical framework. This strategy integrates long-acting pharmacotherapy, routine screening, and harm reduction to interrupt transmission cycles. The primary goal is to maintain a negative status in high-risk individuals while ensuring that those with unrecognized infection are identified and linked to care to achieve viral suppression, thereby preventing further transmission [129][141].
Pre-Exposure Prophylaxis (PrEP)
Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medications by HIV-negative individuals to reduce the risk of acquisition. While daily oral PrEP with tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) remains a standard, adherence is a significant barrier, particularly among adolescent girls, young women (AGYW), and men who have sex with men (MSM) [132][137][139].
Long-Acting and Emerging Modalities
To address adherence challenges, long-acting injectable (LAI) formulations have been developed. Lenacapavir, a first-in-class capsid inhibitor, disrupts HIV replication at multiple stages and is administered via subcutaneous injection every 6 months following an oral loading dose [141]. Other options include the Dapivirine vaginal ring (DVR), which has demonstrated safety and acceptability when initiated in the second trimester of pregnancy [133].
Implementation of LAI-PrEP requires navigating a "bridge period." Unlike oral PrEP, which allows for same-day initiation, LAI-PrEP often involves a 2 to 8 week window between the initial prescription and the first injection to confirm a definitive HIV-negative status, a period that represents a critical point for potential loss to follow-up [146]D.
Post-Exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the administration of antiretroviral medications after a potential exposure to HIV to prevent infection. The 2025 US Public Health Service (PHS) Guidelines emphasize rapid initiation and the use of modern regimens with improved side-effect profiles [129].
Protocol for Occupational Exposure [[Management]]
- Immediate Care: Clean the exposure site (e.g., soap and water for skin, water or saline for mucous membranes) [129].
- Risk Assessment: Evaluate the type of fluid (e.g., blood, semen) and the nature of the exposure (e.g., percutaneous needle stick vs. mucous membrane splash) [129].
- Source Testing: Determine the HIV status of the source individual using rapid testing if possible. If the source has an undetectable viral load, the risk of transmission is negligible, though PEP may still be considered based on clinical judgment [129].
- Initiation: Start PEP as soon as possible, ideally within 2 hours and no later than 72 hours post-exposure [129].
- Regimen: A standard 28-day course of a three-drug antiretroviral regimen is recommended [129].
- Follow-up: Perform HIV testing at baseline, 6 weeks, and 4 months post-exposure using fourth-generation antigen/antibody assays [129].
Screening and Early Detection
Universal and targeted screening are essential to identify the estimated 15% of individuals living with HIV who are unaware of their status. Screening should be integrated into routine care, including family planning, tuberculosis (TB) clinics, and gender-affirming care [40]D[130][151]D.
Screening Guidelines
- Universal Screening: All individuals aged 13–64 should be screened at least once in their lifetime [129].
- High-Risk Populations: MSM, people who inject drugs (PWID), and individuals with multiple sexual partners should be screened at least annually, with some guidelines suggesting every 3–6 months for those at highest risk [149]D.
- Pregnancy: All pregnant women should be screened during the first trimester. In high-prevalence areas, repeat testing in the third trimester is recommended to detect incident infections [130][133].
- Integrated STI Testing: Individuals seeking PrEP or HIV testing should be concurrently screened for Chlamydia trachomatis and Neisseria gonorrhoeae, as bacterial STIs significantly increase the biological risk of HIV acquisition [130][29].
Harm Reduction for People Who Inject Drugs (PWID)
In regions like South Asia, where drug trafficking routes contribute to localized epidemics, harm reduction is the cornerstone of prevention [150]D. Comprehensive services must include:
- Needle and Syringe Programs (NSPs): Providing sterile equipment to prevent the sharing of contaminated needles [135].
- Opioid Agonist Treatment (OAT): Reducing the frequency of injection through medications like methadone or buprenorphine [135].
- Prison-Based Services: Ensuring that incarcerated populations have access to the same prevention and treatment standards as the general community, including ART and OAT [135].
Patient Education and Barriers to Prevention
Effective prevention requires addressing psychological and structural barriers. Stigma—including intersectional stigma related to race, sexual orientation, and gender identity—remains a primary deterrent to PrEP uptake and testing [139][142]. Clinicians should employ "status-neutral" approaches that frame HIV services as part of routine wellness rather than focusing on risk-based labeling [151]D.
Education should also address "status quo bias," where individuals resist transitioning to highly effective prevention (like PrEP) due to a preference for familiar but less effective methods (like inconsistent condom use) [144]D. Digital health interventions, including mobile apps for adherence coaching and peer-referral networks, have shown promise in improving engagement among younger populations [131][132][138].
| Modality | Administration | Target Population | Key Considerations |
|---|---|---|---|
| Oral PrEP (TDF/FTC) | Daily pill | All high-risk groups | Requires high adherence; risk of renal/bone toxicity [133][137] |
| Lenacapavir | Subcutaneous (6-monthly) | AGYW, MSM, PWID | Capsid inhibitor; high persistence; requires oral lead-in [141] |
| Dapivirine Ring | Monthly vaginal ring | Women | Safe in 2nd/3rd trimester; lower systemic absorption [133] |
| PEP | 28-day oral course | Post-exposure (HCP/nPEP) | Must start within 72 hours; 2025 PHS guidelines update [129] |
| TAF Implant | Sub-dermal (annual) | Women/MSM | Under investigation; potential for local site reactions [136] |
| Population | Frequency | Rationale |
|---|---|---|
| General Population (13-64) | Once (Universal) | Identify unrecognized infections in low-risk groups [129] |
| MSM / High-Risk Heterosexuals | Every 3–12 months | High incidence; benefit of early ART and PrEP [149]D |
| Pregnant Women | 1st Trimester (repeat in 3rd) | Prevent vertical transmission; PrEP is safe in pregnancy [130][133] |
| Individuals on RR-TB Treatment | At baseline and follow-up | High vulnerability and missed opportunities for PrEP [40]D |
| Incarcerated Individuals | Upon entry and annually | Disproportionately high rates of injecting drug use [135] |
Guidelines and Resources
- ▸Injectable lenacapavir administered every 6 months is now a CDC-recommended PrEP option as of 2025.
- ▸PEP must be initiated within 72 hours of exposure, though the first dose is ideally administered within 24 hours to maximize efficacy.
- ▸Statin therapy, specifically pitavastatin, is now recommended for primary ASCVD prevention in people with HIV regardless of traditional risk scores.
Clinical of HIV is guided by rapidly evolving evidence regarding antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), and the management of long-term comorbidities. Recent updates in 2024 and 2025 from major international bodies emphasize the transition toward long-acting injectable agents and the aggressive management of cardiovascular and neoplastic risks in an aging population [154][161].
Antiretroviral Therapy (ART) Standards
The International Antiviral Society-USA (IAS-USA) and the European AIDS Clinical Society (EACS) provide the primary frameworks for initiating and maintaining ART. The 2025 EACS Version 13.0 guidelines recommend first-line regimens for adults consisting of a backbone of tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) combined with lamivudine or emtricitabine (XTC), plus an integrase strand transfer inhibitor (INSTI) such as dolutegravir (DTG) or bictegravir (BIC) [154]. Alternatively, dual therapy with DTG plus lamivudine is now supported as a first-line option for most patients [154]. These updates reflect a shift toward minimizing drug exposure while maintaining viral suppression.
Pre-Exposure Prophylaxis (PrEP) Guidelines
PrEP remains a cornerstone of for individuals at increased risk [163]. The most significant practice-changing update in 2025 is the CDC’s recommendation for injectable lenacapavir (LEN), a capsid inhibitor administered subcutaneously every 6 months [155]. This follows the PURPOSE 1 and 2 trials, which demonstrated superior efficacy over daily oral regimens [155].
Canadian 2025 guidelines also emphasize the use of risk assessment tools to identify candidates for PrEP, including men who have sex with men (MSM), people who inject drugs (PWID), and individuals from endemic regions [152]. For those using oral PrEP, the USPSTF continues to recommend tenofovir-based regimens for adolescents and adults [163].
Post-Exposure Prophylaxis (PEP) Protocols
PEP is a medical emergency requiring rapid initiation to prevent viral integration. Guidelines distinguish between occupational (e.g., needlestick) and non-occupational (e.g., sexual assault, condom failure) exposures.
Protocol for Non-Occupational PEP (nPEP) [158]:
- Rapid Assessment: Perform a point-of-care or laboratory-based HIV antigen/antibody test immediately. Do not delay the first dose of nPEP while awaiting results [158].
- Timing: Initiate the first dose as soon as possible, ideally within 24 hours, and no later than 72 hours post-exposure [158].
- Regimen: Administer a 28-day course of a three-drug ART regimen (typically an INSTI-based regimen) [158].
- Follow-up: Re-test for HIV at 4–6 weeks and 3 months post-exposure [129][158].
For occupational exposures, the 2025 US Public Health Service (PHS) guidelines have updated the "window of detection" for modern HIV tests and emphasize that the risk of transmission from a source with an undetectable viral load is negligible [129].
Comorbidity and Screening Guidelines
As the HIV-positive population ages, guidelines have expanded to cover non-communicable diseases and secondary prevention.
- Cardiovascular Health: The DHHS 2025 synopsis recommends pitavastatin (based on the REPRIEVE trial) as primary prevention for atherosclerotic cardiovascular disease (ASCVD) in people with HIV, even those with low-to-moderate traditional risk scores [157].
- Screening: New 2025 Australian and German-Austrian guidelines recommend primary high-risk HPV (HRHPV) testing with cytology triage for MSM and transgender women living with HIV, starting at age 35 [153][165]. General screening for all people living with HIV is recommended starting at age 45 in some jurisdictions [165].
- Cognitive Health: Multidimensional strategies are now recommended to foster healthy cognitive aging, addressing factors like frailty and cardiovascular health that contribute to neurocognitive impairment [162].
- Coinfections: Updated European guidelines for (HSV) emphasize early initiation of therapy to prevent complications like urinary retention or meningism in HIV-coinfected individuals [160]. For pregnant individuals with HIV/HSV coinfection, specific UK guidelines detail management to prevent neonatal transmission [168].
Specialized Clinical Scenarios
- : The WAVE initiative (2025) highlights that while formula feeding is often preferred in high-income settings, shared decision-making regarding breastfeeding is essential for parents with sustained viral suppression [156].
- DoxyPEP: The 2025 BASHH guidelines recommend doxycycline post-exposure prophylaxis (DoxyPEP) for the prevention of syphilis in high-risk groups, including those living with HIV [164].
- Combat Sports: The Association of Ringside Physicians (2026) mandates serum-based HIV testing (not rapid tests) for all fighters within 3 months of competition to ensure safety in blood-prone environments [166].
| Organization | Year | Key Recommendations |
|---|---|---|
| EACS [154] | 2025 | First-line ART: TDF/TAF + XTC + DTG/BIC/DOR; supports dual therapy (DTG+XTC). |
| IAS-USA [161] | 2024 | Updated consensus on ART initiation and long-acting formulations. |
| CDC/US PHS [129][155][158] | 2025 | Approval of 6-month injectable lenacapavir for PrEP; updated nPEP and occupational PEP protocols. |
| DHHS [157] | 2025 | Recommends pitavastatin for primary ASCVD prevention in PWH. |
| ASHM (Australia) [153] | 2025 | Anal cancer screening (HRHPV + cytology) for MSM/trans women starting at age 35. |
| BASHH (UK) [164][167][169] | 2025 | Guidelines for DoxyPEP (syphilis), scabies management, and enteric infections. |
References
- [1]
Houmey MA, Sadek S, Daussy CF et al.. “The Gene Encoding the Antisense Protein ASP of HIV-1: Origin, Distribution and Maintenance.” Viruses (2026). PMID: 41902289 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [2]
Mason LCE, Jawed F, Fruth A et al.. “The natural history of the emergence of sexually transmissible shigellosis.” Microbial genomics (2026). PMID: 41563836 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [3]
Alexiev I, Dimitrova R. “The Origins and Genetic Diversity of HIV-1: Evolutionary Insights and Global Health Perspectives.” International journal of molecular sciences (2025). PMID: 41303393 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [4]
Günthard HF, Kusejko K, Kouyos RD. “Phylogenetics and molecular evolution to understand and curb the HIV pandemic.” Nature reviews. Microbiology (2026). PMID: 40588586 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [5]
Kawashima A, Tsuchiya K, Kuroki K et al.. “Prolonged severe acute respiratory syndrome coronavirus 2 infection and intrahost viral evolution in a severely immunocompromised patient with human immunodeficiency virus infection: A whole-genome sequencing study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41644039 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [6]
Hou Z, Zhang J, Feng H et al.. “A transmission relationship investigation of HIV infection through male-to-male sex among a case of left-behind children with heterosexual orientation in Zhejiang Province of China.” Frontiers in public health (2026). PMID: 41624127 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [7]
Jamal Eddine J, Chalmers EK, Zhou J et al.. “HIV Promoters Isolated from Brain and Peripheral Tissue of Virally Suppressed PWH Are Phylogenetically and Functionally Similar.” International journal of molecular sciences (2026). PMID: 41977374 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [8]
Wu S, Ye L, Zhang X et al.. “Molecular Transmission Dynamics of HIV-1 in Migrant Populations: Transmission Clusters and Demographic Diversity in Hangzhou, a Key Migration Hub in Eastern China.” Viruses (2026). PMID: 41902273 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors - [9]
Mahmood SF, Javed H, Shahbaz A et al.. “Phylogenetic Analysis of an HIV Outbreak in a Dialysis Unit at a Tertiary Care Hospital in Multan, Pakistan.” Viruses (2026). PMID: 41902226 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [10]
Armenia D, Alteri C, Micheli V et al.. “Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing.” The Journal of antimicrobial chemotherapy (2026). PMID: 41826804 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [11]
Yang W, Zhao B, Kang M et al.. “Molecular footprints of a traveling epidemic: CRF01_AE-cluster 5 (01_C5) might spread across Northeast and South China via middle-aged MSM.” Emerging microbes & infections (2026). PMID: 41807290 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [12]
Anderson M, Orf GS, Holzmayer V et al.. “Next-Generation Sequencing Reveals Continued Circulation of Rare HIV-1 Subtypes in the Democratic Republic of the Congo and Refines the Estimate of the Emergence Dates of Three Subtypes.” Viruses (2026). PMID: 41754611 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Miranda MNS, Pimentel V, Santos A et al.. “HIV-1 late diagnosis: Strategies to overcome the misclassification of individuals acutely infected with HIV-1 as individuals diagnosed late.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41722757 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Antonova A, Vinokurov A, Kustova D et al.. “HIV-1 Genetic Diversity and Drug Resistance Mutation Profiles in Donetsk, Luhansk and Zaporizhzhia Regions.” Viruses (2026). PMID: 41600908 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [15]
Banica L, Hohan R, Nicolae I et al.. “Evaluating HIV-1 Transmitted Drug Resistance and Clustering in Newly Diagnosed Patients in Romania (2019-2022).” Viruses (2026). PMID: 41600879 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [16]
Galzitskaya O, Lebedev A, Antonova A et al.. “Genetic Diversity of Vif and Vpr Accessory Proteins in HIV-1 Group M Clades.” Viruses (2026). PMID: 41600877 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
Donoso A, Moreno-Lorenzo M, Delgado E et al.. “Viruses Previously Classified as CRF146_BC, a Circulating Recombinant Form of HIV-1 Recently Reported in Brazil, Represent Different Recombinant Forms, One of Which Is Circulating in Spain.” Viruses (2026). PMID: 41600864 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [18]
Zhang Q, Yan M, Huang J et al.. “Molecular Epidemiological Surveillance of HIV-1 Genotypes and Drug Resistance Profiles in Wuhan, Central China.” Viruses (2025). PMID: 41600820 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [19]
Kovalenko G, Liulchuk MG, Filippovych M et al.. “VANTAGE: van-based real-time HIV sequencing for transmission mapping and drug resistance profiling in war-affected Ukraine.” AIDS (London, England) (2026). PMID: 41489325 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Mei J, Li J, Chen X et al.. “Characteristics and Influencing Factors Among Newly Diagnosed HIV-1 Patients with Non-Marital, Non-Commercial Heterosexual Contact in Lishui, China (2020-2024).” Viruses (2025). PMID: 41472295 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Asgai AS, Derse TK, Kidie DM et al.. “Prevalence of Hypertension and Associated Factors Among People Living with HIV in Ethiopia: A Systematic Review and Meta-Analysis.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 41989048 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [22]
Ma Y, Zhang X, He Y et al.. “Prevalence and associated factors of ICD/DSM-diagnosed depressive disorders among people living with HIV: A systematic review and meta-analysis.” Journal of affective disorders (2026). PMID: 41806928 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [23]
Njiro BJ, Bwire GM. “Surveillance of HIV-1 drug resistance in Tanzania across the pre- and post-dolutegravir eras: A systematic review and meta-analysis.” Journal of infection and public health (2026). PMID: 41795240 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Management - [24]
Kasujja FX, Aikaeli F, Garrib A et al.. “Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.” Lancet (London, England) (2026). PMID: 41831847 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [25]
Ruiz-Palacios GM, Cahn PE, Halperin SA et al.. “Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.” Vaccine (2026). PMID: 41785679 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [26]
Al-Shuaili HH, Al-Busafi SA, Al Busafi SS et al.. “Impact of Hepatitis B Exposure and/or HIV Co-Infection on Clinical Outcomes in Chronic Hepatitis C Patients in Oman: An Ambidirectional Cohort Study.” Journal of medical virology (2026). PMID: 41949324 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [27]
Amogne MD, Kebede A, Asfaw D et al.. “Survival and predictors of mortality among people living with HIV (PLHIV) on antiretroviral therapy in Ethiopia (2016-2023): a retrospective cohort study.” BMJ open (2026). PMID: 41887650 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Management, Prognosis and Long-term Outcomes - [28]
Roberts NLS, Ruselu G, Fadhil S et al.. “Longitudinal Blood Pressure Trajectory and Subclinical Echocardiographic Measures of Cardiovascular Disease in People Living With HIV: A Comparative Prospective Cohort Study.” Journal of the American Heart Association (2026). PMID: 41878841 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [29]
Mukasa D, Kinuthia J, Meisner A et al.. “Oral preexposure prophylaxis use and the risk of bacterial sexually transmitted infections and HIV among African women: A prospective observational cohort study.” PLoS medicine (2026). PMID: 41802176 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Prevention and Screening - [30]
Kim S, Baek YJ, Lee E et al.. “Clinical Characteristics and Risk Factors for Syphilis Among People Living With Human Immunodeficiency Virus: A Nationwide Population-Based Cohort Study in Korea.” Journal of Korean medical science (2026). PMID: 41978926 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [31]
Tsai YT, Mudiyanselage SPK, Chuang TJ et al.. “Effect of Substance Abuse on Suicidal Behaviors Among People Living With HIV: 11-Year Cohort Study.” The journal of nursing research : JNR (2026). PMID: 41811732 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [32]
Auca A, Shalah Logose B, Izudi J. “Underweight is associated with detectable viral load among adolescents with HIV in rural eastern Uganda: a retrospective cohort study.” Journal of health, population, and nutrition (2026). PMID: 41795105 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Management - [33]
Simegn MB, Geremew H, Chinkey FD et al.. “Inconsistent condom use and its associated factors among female sex workers in African countries: Systematic review and meta-analysis.” PloS one (2026). PMID: 41961838 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [34]
Inzaule S, Waasila J, Silva R et al.. “High risk of COVID-19 mortality in people living with advanced HIV disease in South Africa: A retrospective cohort study.” Medicine (2026). PMID: 41961721 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [35]
Del Moral Trinidad LE, Andrade Villanueva JF, Ruíz Mora LA et al.. “Factors Associated With Loss to Follow-Up Among People Living With HIV in a National Tertiary Care Hospital: Protocol and Baseline Analysis of a Prospective Cohort Study.” JMIR research protocols (2026). PMID: 41849639 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Management - [36]
Asaga PM, Kroeger A, Omilabu S et al.. “HIV treatment failure in tertiary care: clinical epidemiology and preliminary mechanistic characterisation.” Frontiers in public health (2026). PMID: 41994513 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management - [37]
Lazarus G, Kawi NH, Luis H et al.. “A Four-Item Risk Score to Target Acute HIV Infection Testing Among Men Who Have Sex With Men in Indonesia: Development and Validation in the INTERACT Prospective Cohort.” Journal of the International AIDS Society (2026). PMID: 41987569 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Ikeuchi K, Okushin K, Arisato Y et al.. “Trends and characteristics of syphilis incidence in Japan: a nationwide claims-based analysis of working-age populations and their dependents, 2016-2023.” BMJ open (2026). PMID: 41985946 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [39]
Schnure M, Forster R, Jones JL et al.. “Projected Increase in HIV Incidence in 11 States if Ryan White Ends: A Simulation Study.” American journal of public health (2026). PMID: 41950444 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [40]
Leonard A, Lowensen K, Di Giacomo E et al.. “Missed PrEP opportunities and vulnerability to HIV during rifampicin-resistant tuberculosis treatment in South Africa.” Frontiers in public health (2026). PMID: 41948027 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [41]
Edwards JS, De Paris K. “Inflammation at the maternal-fetal interface: a perspective on interacting risk factors for preterm birth in sub-Saharan African women living with HIV.” Frontiers in immunology (2026). PMID: 41918737 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [42]
Willkens M, Issarow B, Etyang AO et al.. “Ambulatory Blood Pressure Patterns and Left Ventricular Mass Index in Tanzanian Adults Living with and without HIV.” Global heart (2026). PMID: 41908163 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [43]
Osborne A, Kamara IF, Lakoh S et al.. “Advancing Toward the UNAIDS 95-95-95 Targets in Sierra Leone: A Narrative Review of Progress, Persistent Gaps, and Policy Priorities.” Annals of global health (2026). PMID: 41907565 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Management - [44]
Alava-Flores WG, Navarro-Del-Aguila I, Otero-Rodriguez S et al.. “HIV/HTLV-1/2 Co-Infection in the Peruvian Amazon: Prevalence and Associated Factors.” Viruses (2026). PMID: 41902246 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Deng M, Sun Y, Yang X et al.. “Survival outcomes and influencing factors in Zhengzhou HIV/AIDS patients following antiretroviral therapy initiation (2014-2024): a retrospective cohort analysis.” Frontiers in public health (2026). PMID: 41889608 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management - [46]
Akullian A, Ssempijja V, Bridenbecker D et al.. “Evaluating the biomedical and behavioral drivers of HIV incidence decline in adolescent girls and young women in Uganda: A mathematical modeling study.” PLoS medicine (2026). PMID: 41880347 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [47]
Zhao L, Tang L, Yang X et al.. “Association rule mining and network analysis of the evolving comorbidity patterns in HIV inpatients in Baise, China.” Frontiers in public health (2026). PMID: 41869604 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [48]
Balde I, Toure AA, Abbate JL et al.. “Spatial distribution of HIV prevalence and associated factors in Guinea: retrospective cross-sectional study using Demographic and Health Surveys (DHS) data from 2012 and 2018.” BMJ open (2026). PMID: 41856575 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [49]
Machalek DA, Nyemba DC, Travill D et al.. “Population impact of South Africa's human papillomavirus (HPV) vaccination programme on HPV prevalence in adolescent girls with and without HIV: a repeat cross-sectional study.” The Lancet. Global health (2026). PMID: 41856140 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
Khamrong C, Thammalangka R, Kotchawat K et al.. “Effects of Music and Counseling Programs on Mental Health and Antiretroviral Treatment Adherence of Adolescents and Young Adults Living With HIV in Northern Thailand, a Randomized Trial.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 41944194 ↗
L1bRCTCited in: Management - [51]
Zheng A, Fox MP, Greener R et al.. “Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation.” Annals of epidemiology (2026). PMID: 41819297 ↗
L1bRCTCited in: Management - [52]
Schönenberger CM, Haenggi K, Ringera IK et al.. “HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial.” The Journal of antimicrobial chemotherapy (2026). PMID: 41793741 ↗
L1bRCTCited in: Management - [53]
Nontamo S, Kamsu GT, Madolo NA et al.. “Implementation Lessons and Policy Implications of Same-Day Antiretroviral Therapy Initiation: Insights from the ART Same-Day Counselling and Initiation (ASCI) SOP in South Africa.” International journal of environmental research and public health (2026). PMID: 41899755 ↗
L1bRCTCited in: Management - [54]
Zhu X, Zou M. “Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz.” Medicine (2026). PMID: 41961664 ↗
L1bRCTCited in: Management - [55]
Assefa GW, Yimer TY, Tassew WC. “Rate of Viral Resuppression and Predictors Among PLHIV on Second-Line Antiretroviral Therapy at Gondar Comprehensive Specialized Hospital, Northwest, Ethiopia: A Retrospective Cohort Study.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 41925089 ↗
L2bCOHORTCited in: Management - [56]
Li R, Liu L, Wang R et al.. “Immune reconstitution efficacy and associated risk factors for immunological non-response in people living with HIV during long-term antiretroviral therapy: a single-center retrospective cohort study at a tertiary care hospital in China.” Frontiers in immunology (2026). PMID: 41909684 ↗
L2bCOHORTCited in: Management, Prognosis and Long-term Outcomes - [57]
Alzate-Ángel JC, Sussmann O, Andrade J et al.. “Initial Antiretroviral Third-Drug Class and Time to Loss of Virologic Suppression: A Real-World Colombian Cohort Study.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 41889372 ↗
L2bCOHORTCited in: Management - [58]
Mashiri CE, Chifurira R, Chinhamu K et al.. “Determinants of CD4 count recovery among severely immunosuppressed HIV patients initiated on antiretroviral therapy: a prospective cohort study in KwaZulu-Natal, South Africa.” Frontiers in public health (2026). PMID: 41859266 ↗
L2bCOHORTCited in: Management - [59]
Brazier E, Romo ML, Ciaranello AL et al.. “Lingering sex and age disparities in dolutegravir uptake among adults with HIV: a multicountry observational cohort study.” BMJ global health (2026). PMID: 41825914 ↗
L2bCOHORTCited in: Management - [60]
Chongyangyuenvong P, Kiertiburanakul S. “Changes in Metabolic Parameters After Switching From Efavirenz to Dolutegravir-Based Regimen: A Cohort Study in Thai People Living With HIV.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 41805453 ↗
L2bCOHORTCited in: Management - [61]
Mengistie BA, Aragaw GM, Mulatu GG et al.. “Virologic suppression among HIV-positive pregnant and lactating women receiving antiretroviral therapy in Africa: A systematic review and meta-analysis.” PloS one (2026). PMID: 41973701 ↗
L2aSR_OBSCited in: Management - [62]
Kankundiye P, Kia P, Kankaka E et al.. “Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa.” Frontiers in immunology (2026). PMID: 41972133 ↗
L5REVIEW_NARRATIVECited in: Management - [63]
Poisson L, Hingrat QL, Lermechain F et al.. “HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab.” Journal of medical virology (2026). PMID: 41964438 ↗
L5OTHERCited in: Management - [64]
Khimani K, Muhihi A, Fawzi WW et al.. “Depressive Symptoms and Clinical and Nutritional Outcomes among Adults Living with HIV Initiating Antiretroviral Therapy in Dar es Salaam, Tanzania.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 41949433 ↗
L5OTHERCited in: Management - [65]
Ferrara M, Maccario V, Barrera F et al.. “The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV.” The Journal of antimicrobial chemotherapy (2026). PMID: 41937337 ↗
L5OTHERCited in: Management - [66]
Bolas AF, Caixas U, Bogalho P et al.. “Thyroid Function Screening in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 41925153 ↗
L5OTHERCited in: Management - [67]
Chen J, Yang G, Tian L et al.. “Uracil derivatives as non-nucleoside inhibitors targeting HIV-1 reverse transcriptase.” European journal of medicinal chemistry (2026). PMID: 41916231 ↗
L5REVIEW_NARRATIVECited in: Management - [68]
Zhou Y, Zuo H, Luo S et al.. “Medication Burden and Adherence of Antiretroviral Therapy Among Older People Living with HIV in the Context of Multimorbidity and Polypharmacy: A Multicenter Study.” Viruses (2026). PMID: 41902295 ↗
L5OTHERCited in: Management - [69]
Jones JE, Gunderson CE, Wigdahl B et al.. “Breaking into HIV-1's Epigenetic Vault: Cure Strategies to Eliminate the Viral Reservoir.” Viruses (2026). PMID: 41902262 ↗
L5REVIEW_NARRATIVECited in: Management - [70]
Alaei K, Kwan B, Lounsbery CP et al.. “Viral Suppression Among People Living with HIV in Tajikistan: A Nationwide Analysis.” Viruses (2026). PMID: 41902255 ↗
L5OTHERCited in: Management - [71]
Tang JW, Olszyna DP, Stephenson I et al.. “HIV-Now Another Long Term Chronic Condition?” Viruses (2026). PMID: 41902191 ↗
L5REVIEW_NARRATIVECited in: Management - [72]
Yanamadala Y, Gokulan K, Karn K et al.. “Gestational and lactational exposure to HIV tri-combination therapy induces sex- and dose-dependent changes in inflammatory cytokine profiles, intestinal permeability, and villi morphology in adult rat offspring.” Frontiers in immunology (2026). PMID: 41890730 ↗
L5OTHERCited in: Management - [73]
Prosty C, Katergi K, Sorin M et al.. “Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024). PMID: 38583518 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [74]
Gerber F, Semphere R, Lukau B et al.. “Same-day versus rapid ART initiation in people with HIV and symptoms of tuberculosis (SaDAPT): a randomised, non-inferiority trial in Lesotho and Malawi.” The lancet. HIV (2026). PMID: 41692011 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [75]
Meya DB, Nalintya E, Skipper CP et al.. “Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV-Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39044381 ↗
L1bRCTCited in: Supportive Care and Complication Management - [76]
Nabipur L, Mouawad M, Venketaraman V. “Additive Effects of Glutathione in Improving Antibiotic Efficacy in HIV-M.tb Co-Infection in the Central Nervous System: A Systematic Review.” Viruses (2025). PMID: 39861915 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [77]
Azzam A, Khaled H, Salem H et al.. “The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak.” Virology journal (2024). PMID: 38840177 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [78]
Choshi P, Pedretti S, Chimbetete T et al.. “The association of class II HLA alleles with tuberculosis-associated immune reconstitution inflammatory syndrome.” PLoS pathogens (2025). PMID: 40972103 ↗
L1bRCTCited in: Supportive Care and Complication Management - [79]
Nikjeh O, Rejali S, Sasaninia K et al.. “Overcoming Treatment Challenges in HIV-Associated Mycobacterial Diseases: New Therapeutic Frontiers.” International journal of molecular sciences (2025). PMID: 41226364 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [80]
Clemente T, Papaioannu-Borjesson R, Castagna A et al.. “Addressing late HIV presentation: the current knowledge and unmet needs.” Expert review of anti-infective therapy (2025). PMID: 40622104 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [81]
Gopal A, Jose A, Singh BK et al.. “Rheumatic manifestations of HIV/AIDS.” Best practice & research. Clinical rheumatology (2025). PMID: 40374411 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [82]
Rangaraj S, Agarwal A, Banerjee S. “Bird's Eye View on Mycobacterium tuberculosis-HIV Coinfection: Understanding the Molecular Synergism, Challenges, and New Approaches to Therapeutics.” ACS infectious diseases (2025). PMID: 40229972 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [83]
Vaselli NM, Salaveria K, Winearls J et al.. “Pneumocystis jirovecii pneumonia-Immune reconstitution inflammatory syndrome: A review of published cases.” HIV medicine (2025). PMID: 40129097 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [84]
Sossen B, Kubjane M, Meintjes G. “Tuberculosis and HIV coinfection: Progress and challenges towards reducing incidence and mortality.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40064284 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [85]
Mitchell CD. “Prevention, Diagnosis, and Treatment of Tuberculosis in Children with Human Immunodeficiency Virus.” Clinics in perinatology (2024). PMID: 39487023 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [86]
Le X, Shen Y. “Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis.” Viruses (2024). PMID: 38675837 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [87]
Górecka A, Majewski S, Szymańska E et al.. “Skin and mucosal manifestations of immune reconstitution inflammatory syndrome in people living with HIV: a review.” International journal of dermatology (2024). PMID: 38426349 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [88]
Musubire A, Kagimu E, Mugabi T et al.. “Complex Decisions in HIV-Related Cryptococcosis: Addressing Second Episodes of Cryptococcal Meningitis.” Current HIV/AIDS reports (2024). PMID: 38400871 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [89]
Rodrigues Alves N, Barão C, Mota C et al.. “Immune recovery uveitis: a focus review.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2024). PMID: 38381160 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [90]
Wang M, Cui Y, Shi J et al.. “Difficulty in diagnosing intracranial infection caused by Mycobacterium avium in an AIDS patient: case report and review of the literature.” Diagnostic pathology (2024). PMID: 38982440 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [91]
Duong MT, Ungemach A, Malik F et al.. “Mycobacterial spindle cell pseudotumor of the spinal cord: Case report and literature review.” Journal of neuroimmunology (2024). PMID: 38554665 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [92]
Wang W, Tang S, Yang J et al.. “Individualized immunotherapy for immune reconstitution-associated cortical encephalitis in an HIV-positive cryptococcal meningitis patient: a case report.” Frontiers in immunology (2026). PMID: 41983125 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [93]
Chenchula S, Amerneni KC, Rajakarunakaran P et al.. “Mpox Clinical Outcomes in People With and Without HIV Treated With Tecovirimat: A Systematic Review.” Reviews in medical virology (2026). PMID: 41995224 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [94]
Orkin C, Ruane PJ, Hedgcock M et al.. “Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.” Lancet (London, England) (2026). PMID: 41763229 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [95]
Ogbuagu O, Gaur A, McMahon JH et al.. “Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study.” The Lancet. Microbe (2026). PMID: 41720146 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [96]
Shelley D, Armstrong-Hough M, Nguyen T et al.. “Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial.” The Lancet. Global health (2026). PMID: 41713442 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [97]
Borjabad B, Rojas J, Inciarte A et al.. “Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study.” The Journal of antimicrobial chemotherapy (2026). PMID: 41676981 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [98]
Colson AE, Mills AM, Ramgopal MN et al.. “Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.” Lancet (London, England) (2026). PMID: 41654375 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [99]
Orkin C, Mngqibisa R, Velez JD et al.. “Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.” Lancet (London, England) (2026). PMID: 41654374 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [100]
Nega AD, Asemahagn MA, Getahun FA. “Effectiveness of differentiated antiretroviral therapy delivery models for stable persons living with HIV in Africa: a systematic review and meta-analysis.” AIDS research and therapy (2026). PMID: 41582132 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [101]
Nirmalkar AP, Mamulwar M, Godbole S et al.. “Cost-effectiveness of cervical cancer screening among women living with HIV in India: study protocol.” BMJ open (2026). PMID: 41617241 ↗
L2bTRIAL_NONRANDOMCited in: Prognosis and Long-term Outcomes - [102]
Ishikawa K, Muramatsu T, Kaneko S et al.. “A Retrospective Cohort Study on HHV-8 Viral Load and Prognosis in HIV-Associated Kaposi Sarcoma Among People Living with HIV in Japan.” Viruses (2026). PMID: 41754504 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [103]
Mlambo Z, Ramdin S, Green-Thompson R et al.. “Impact of maternal HIV infection on pregnancy and labor complication and perinatal health outcomes: a South African retrospective study.” Archives of gynecology and obstetrics (2026). PMID: 41711938 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [104]
Amubuomombe PP, Itsura P, Tonui PK et al.. “Pregnancy outcomes among women with and without HIV infections who underwent excisional treatment for high-grade cervical intraepithelial neoplasia: a retrospective cohort study in low-resource settings.” BMJ open (2026). PMID: 41708173 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [105]
Mogashoa T, Ngom JT, Choga OT et al.. “High treatment success among individuals with rifampicin-resistant tuberculosis in Botswana: A retrospective cohort study.” Journal of infection and public health (2026). PMID: 41671595 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [106]
Hu J, Fang Y, Ma S et al.. “Novel inflammatory metabolic parameters as predictors of metabolic dysfunction-associated fatty liver disease in people living with HIV receiving antiretroviral therapy: a retrospective cohort study.” Frontiers in public health (2026). PMID: 41647742 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [107]
Virseda-Berdices A, Requena B, Berenguer J et al.. “Lipid and immune dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV-coinfected participants with cACLD: a retrospective study.” Frontiers in immunology (2025). PMID: 41601646 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [108]
Kassaw AT, Teferi ET, Tarekegn GY et al.. “Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV/AIDS in a Multi-Center Cohort Study.” Cancer control : journal of the Moffitt Cancer Center (2026). PMID: 41830587 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [109]
Shahid S, Karimi H, Ahmad B et al.. “Outcomes of isoniazid preventive therapy in pregnant women living with HIV: A systematic review and meta-analysis.” International journal of immunopathology and pharmacology (2026). PMID: 41824367 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [110]
Hasani M, Muzammil FM, Thahira M et al.. “Severe necrotic and fatal monkeypox in HIV-infected patients.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41713695 ↗
L4CASE_REPORTCited in: Prognosis and Long-term Outcomes - [111]
Majeed I, Hannan KS, Buckley A et al.. “Epstein-Barr virus (EBV)-associated smooth muscle tumor of the central nervous system in an HIV patient: diagnostic and therapeutic challenges.” BMC infectious diseases (2026). PMID: 41639789 ↗
L4CASE_REPORTCited in: Prognosis and Long-term Outcomes - [112]
Casas-Aparicio G, Soto-Abraham V, Torres-Ruíz F et al.. “Complete remission of HIV-associated glomerular disease with tacrolimus, followed by late-onset Kaposi sarcoma: A report of two cases.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41581649 ↗
L4CASE_REPORTCited in: Prognosis and Long-term Outcomes - [113]
Asensi V, Cabo R, García R et al.. “Y181C-associated virologic failure during long-acting injectable cabotegravir/Rilpivirine in a patient engaged in intensive intravenous Chemsex.” HIV medicine (2026). PMID: 41574768 ↗
L4CASE_REPORTCited in: Prognosis and Long-term Outcomes - [114]
Starks TJ, Hillesheim JR, Castiblanco J et al.. “Adapted Motivational Interviewing Reduces Substance Use and Sexual Risk Taking Among Partnered Sexual Minority Men Aged 18-35 Years: Results of the PARTNER Study.” Journal of acquired immune deficiency syndromes (1999) (2026). PMID: 41343494 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [115]
Diggs MR, Umbleja T, McCallum S et al.. “Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial.” The lancet. HIV (2025). PMID: 40180472 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [116]
Pelchen-Matthews A, Mocroft A, Ryom L et al.. “Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.” Kidney international (2024). PMID: 38697479 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [117]
Deese J, Chen PL, Gao X et al.. “Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.” AIDS and behavior (2023). PMID: 36357806 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [118]
Beesham I, Mansoor LE, Joseph Davey DL et al.. “Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.” Journal of acquired immune deficiency syndromes (1999) (2022). PMID: 35972853 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [119]
Bunjun R, Ramla TF, Jaumdally SZ et al.. “Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35941737 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [120]
Tanko RF, Bunjun R, Dabee S et al.. “The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.” The Journal of infectious diseases (2022). PMID: 35263421 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [121]
Singata-Madliki M, Lawrie TA, Balakrishna Y et al.. “Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.” Reproductive health (2021). PMID: 34587971 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [122]
Donnell D, Beesham I, Welch JD et al.. “Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.” The lancet. HIV (2021). PMID: 34126052 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [123]
Beesham I, Welch JD, Heffron R et al.. “Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.” Journal of the International AIDS Society (2020). PMID: 32396700 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [124]
Ghazi L, Baker JV, Sharma S et al.. “Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial.” American journal of hypertension (2020). PMID: 31800000 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [125]
Sereti I, Gulick RM, Krishnan S et al.. “ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.” Journal of acquired immune deficiency syndromes (1999) (2019). PMID: 31241541 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [126]
Sathyamala C. “In the name of science: Ethical violations in the ECHO randomised trial.” Global public health (2022). PMID: 31234717 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [127]
Ekenberg C, Tang MH, Zucco AG et al.. “Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.” The Journal of infectious diseases (2019). PMID: 31219150 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [128]
Boatman JA, Baker JV, Emery S et al.. “Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial.” Journal of acquired immune deficiency syndromes (1999) (2019). PMID: 30664075 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [129]
Kofman AD, Struble KA, Heneine W et al.. “2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare Settings.” Infection control and hospital epidemiology (2025). PMID: 41569270 ↗
L1cGUIDELINECited in: Prevention and Screening, Guidelines and Resources - [130]
Mogaka JN, Mugambi M, Abuna F et al.. “Prevalence and Incidence of Chlamydia trachomatis and Neisseria gonorrhoeae Among Women Who Initiated HIV PrEP During Pregnancy in Kenya.” Journal of acquired immune deficiency syndromes (1999) (2026). PMID: 41954102 ↗
L1bRCTCited in: Prevention and Screening - [131]
Ortblad KF, Wairimu N, Culquichicon C et al.. “Effect of enhanced peer PrEP referral with HIV self-testing delivery among young Kenyan women: A randomized controlled trial of peer networks.” PLoS medicine (2026). PMID: 41911315 ↗
L1bRCTCited in: Prevention and Screening - [132]
Hightow-Weidman L, Choi SK, Yigit I et al.. “Improving Pre-Exposure Prophylaxis Adherence in People at Risk for HIV: Secondary Analysis of a Digital Health Intervention to Enhance User Engagement.” JMIR mHealth and uHealth (2026). PMID: 41805538 ↗
L1bRCTCited in: Prevention and Screening - [133]
Mhlanga FG, Szydlo DW, Mayo AJ et al.. “Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial.” The lancet. HIV (2026). PMID: 41687672 ↗
L1bRCTCited in: Prevention and Screening - [134]
Habtie TE, Feleke SF, Chanie GM et al.. “Global Perspectives on Pre-Exposure Prophylaxis: A Systematic Review and Meta-Analysis of Health Care Providers' Awareness, Willingness, and Barriers.” AIDS patient care and STDs (2026). PMID: 41761621 ↗
L2aSR_OBSCited in: Prevention and Screening - [135]
Santo T, Hickman M, Altice FL et al.. “Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review.” The International journal on drug policy (2026). PMID: 41651702 ↗
L2aSR_OBSCited in: Prevention and Screening - [136]
Gengiah TN, Lewis L, Harkoo I et al.. “Impact of Tenofovir Alafenamide Sub-Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa.” Journal of the International AIDS Society (2026). PMID: 41987600 ↗
L2bTRIAL_NONRANDOMCited in: Prevention and Screening - [137]
Busang J, Zuma T, Chimbindi N et al.. “Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation.” BMC public health (2026). PMID: 41559582 ↗
L2bTRIAL_NONRANDOMCited in: Prevention and Screening - [138]
Mercadal-Orfila G, Serrano JI, Mijares T et al.. “Digital Monitoring of Pre-Exposure Prophylaxis Users Through Electronic Patient-Reported Outcome Measures and Electronic Patient-Reported Experience Measures: Multicenter Prospective Study on Feasibility, Safety, and Predictive Modeling of Digital Engagement.” Journal of medical Internet research (2026). PMID: 41973627 ↗
L2bCOHORTCited in: Prevention and Screening - [139]
Stangl AL, Bryan C, Barré I et al.. “The influence of stigma on PrEP uptake among adolescent girls and young women in Johannesburg, South Africa and Mwanza, Tanzania: Qualitative findings from the EMPOWER study.” PloS one (2026). PMID: 41632776 ↗
L1bRCTCited in: Prevention and Screening - [140]
Hampanda K, Amstutz A, Nayame L et al.. “TwySHE-an mHealth peer-navigator intervention to increase PrEP and contraceptive use among female university students in Zambia: study protocol of a hybrid effectiveness-implementation randomized controlled trial.” Trials (2026). PMID: 41781994 ↗
L2bTRIAL_NONRANDOMCited in: Prevention and Screening - [141]
Ebrahim S, Gloeck N, Adam Z et al.. “Lenacapavir as pre-exposure prophylaxis for HIV prevention.” The Cochrane database of systematic reviews (2026). PMID: 41919720 ↗
L2aSR_OBSCited in: Prevention and Screening - [142]
Smith LR, Algarin AB, Pitpitan EV et al.. “A Novel Social Network Approach to Measure Intersectional Stigma Among Latino Men Who Have Sex With Men in San Diego, California (NEXUS): Protocol for a Longitudinal Cohort Study.” JMIR research protocols (2026). PMID: 41773656 ↗
L2bCOHORTCited in: Prevention and Screening - [143]
Xu J, Dai Z, Qiu Y et al.. “A Multilevel Network Peer Intervention Among Student Men Who Have Sex With Men Attending University: Protocol for an Implementation-Effectiveness Before-After Cohort Study.” JMIR research protocols (2026). PMID: 41576294 ↗
L2bCOHORTCited in: Prevention and Screening - [144]
Zhao M, Li S, Zhao X et al.. “Moderating Role of Condom-Use Inertia on the Association Between Status Quo Bias and Pre-Exposure Prophylaxis Resistance Intention Among Chinese Men Who Have Sex With Men: Cross-Sectional Study.” JMIR public health and surveillance (2026). PMID: 41962129 ↗
L5OTHERCited in: Prevention and Screening - [145]
Hlongwa M, Tsai AC, Choko A. “Integration of PrEP dispensing with HIV self-testing among heterosexual men in Sub-Saharan Africa: protocol for a scoping review.” BMJ open (2026). PMID: 41927492 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [146]
Demidont ACA. “Bridging the Gap: The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention.” Viruses (2026). PMID: 41902244 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [147]
Collins LB, Le A, Nicol MR. “Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model.” The Journal of antimicrobial chemotherapy (2026). PMID: 41873439 ↗
L5OTHERCited in: Prevention and Screening - [148]
Cordova E, Sokhela S, Alagaratnam J et al.. “Overcoming barriers, driving progress: Clinical science at IAS 2025.” Journal of the International AIDS Society (2026). PMID: 41867101 ↗
L5OTHERCited in: Prevention and Screening - [149]
Wu Z, Zhang X, Zhang X et al.. “HIV Risk Profiles and Pre-Exposure Prophylaxis and Postexposure Prophylaxis Uptake Among Men Who Have Sex With Men in China: Cross-Sectional Latent Class Analysis.” JMIR public health and surveillance (2026). PMID: 41813429 ↗
L5OTHERCited in: Prevention and Screening - [150]
Rahman MF, Khan MSI, Shiddiky MJA et al.. “An update on bloodborne viruses among people who inject drugs in South Asia.” Harm reduction journal (2026). PMID: 41807975 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [151]
O'Brien CS, Kyweluk M, Dowshen N et al.. “Clinician Perspectives on Integrating Biomedical HIV Prevention with Gender-Affirming Care Delivered via Telehealth.” AIDS patient care and STDs (2026). PMID: 41805004 ↗
L5OTHERCited in: Prevention and Screening - [152]
Tan DHS, Hull MW, Onyegbule SO et al.. “Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.” CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2025). PMID: 41326046 ↗
L1cGUIDELINECited in: Guidelines and Resources - [153]
Poynten IM, Turner RC, Varma R et al.. “Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.” HIV medicine (2025). PMID: 41130598 ↗
L1cGUIDELINECited in: Guidelines and Resources - [154]
Ambrosioni J, Levi LI, Alagaratnam J et al.. “Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025.” HIV medicine (2026). PMID: 41088922 ↗
L1cGUIDELINECited in: Guidelines and Resources - [155]
Patel RR, Hoover KW, Lale A et al.. “Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025.” MMWR. Morbidity and mortality weekly report (2025). PMID: 40966169 ↗
L1cGUIDELINECited in: Guidelines and Resources - [156]
Keane A, Haberl L, Aho I et al.. “European Guidelines on HIV and breastfeeding: "Same, same, but different" - Results from a WAVE survey.” HIV medicine (2025). PMID: 40853074 ↗
L1cGUIDELINECited in: Guidelines and Resources - [157]
Beavers C, Pau AK, Glidden D et al.. “Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.” Annals of internal medicine (2025). PMID: 40418812 ↗
L1cGUIDELINECited in: Guidelines and Resources - [158]
Tanner MR, O'Shea JG, Byrd KM et al.. “Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025.” MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2025). PMID: 40331832 ↗
L1cGUIDELINECited in: Guidelines and Resources - [159]
Alhusayen R, Dienes S, Lam M et al.. “North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations.” Journal of the American Academy of Dermatology (2025). PMID: 39725212 ↗
L1cGUIDELINECited in: Guidelines and Resources - [160]
Patel R, Moran B, Clarke E et al.. “2024 European guidelines for the management of genital herpes.” Journal of the European Academy of Dermatology and Venereology : JEADV (2025). PMID: 39620271 ↗
L1cGUIDELINECited in: Guidelines and Resources - [161]
Gandhi RT, Landovitz RJ, Sax PE et al.. “Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.” JAMA (2025). PMID: 39616604 ↗
L1cGUIDELINECited in: Guidelines and Resources - [162]
Cysique LA, Levin J, Howard C et al.. “Fostering healthy cognitive ageing in people living with HIV.” The lancet. HIV (2025). PMID: 39615509 ↗
L1cGUIDELINECited in: Guidelines and Resources - [163]
Barry MJ, Nicholson WK, Silverstein M et al.. “Preexposure Prophylaxis to Prevent Acquisition of HIV: US Preventive Services Task Force Recommendation Statement.” JAMA (2023). PMID: 37606666 ↗
L1cGUIDELINECited in: Guidelines and Resources - [164]
Saunders J, Deering J, Dewsnap C et al.. “British Association for Sexual Health and HIV (BASHH) UK national guideline for the use of doxycycline post-exposure prophylaxis (DoxyPEP) for the prevention of syphilis, 2025.” International journal of STD & AIDS (2025). PMID: 40505019 ↗
L1cGUIDELINECited in: Guidelines and Resources - [165]
Chromy D, Aigner F, Becker JC et al.. “German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV.” Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2025). PMID: 40320909 ↗
L1cGUIDELINECited in: Guidelines and Resources - [166]
Giovane RA, deWeber K, Sauceda U et al.. “Blood-Borne Infection Prevention in Combat Sports: Position Statement of the Association of Ringside Physicians.” Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine (2026). PMID: 40197438 ↗
L1cGUIDELINECited in: Guidelines and Resources - [167]
Morris G, Haddow L, Sashidharan PN et al.. “British Association for Sexual Health and HIV National Guideline on the Management of Scabies in adults 2025.” International journal of STD & AIDS (2025). PMID: 40103364 ↗
L1cGUIDELINECited in: Guidelines and Resources - [168]
Clarke E, Patel R, Dickins D et al.. “Joint British Association for Sexual Health and HIV and Royal College of Obstetricians and Gynaecologists national UK guideline for the management of herpes simplex virus (HSV) in pregnancy and the neonate (2024 update).” International journal of STD & AIDS (2025). PMID: 39348176 ↗
L1cGUIDELINECited in: Guidelines and Resources - [169]
Richardson D, Pakianathan M, Ewens M et al.. “British Association of Sexual Health and HIV (BASHH) United Kingdom national guideline for the management of sexually transmitted enteric infections 2023.” International journal of STD & AIDS (2023). PMID: 37247427 ↗
L1cGUIDELINECited in: Guidelines and Resources - [170]
Marcinkiewicz A, Walusiak-Skorupa J, Wdówik P et al.. “[Guidance for the occupational medicine service regarding the prevention of hepatitis C and HIV infection in Poland].” Medycyna pracy (2024). PMID: 39323355 ↗
L1cGUIDELINECited in: Guidelines and Resources